A BUDGET IMPACT ANALYSIS TO ESTIMATE THE ECONOMIC IMPACT OF DRUG ELUTING BALLOON FOR THE TREATMENT OF PERIPHERAL VASCULAR DISEASE
Author(s)
Corbo M*1;Beccagutti G1, Manda B2 1Medtronic Italia, Sesto San Giovanni, Italy, 2Medtronic Vascular Inc., Santa Rosa, CA, USA
Presentation Documents
OBJECTIVES: Drug Eluting Balloon (DEB) is a promising alternative for the treatment of patients with peripheral arterial disease, due to the potential reduction in re-intervention rates and cost-savings compared to other technologies commonly used. The objective of this analysis was to assess the economic impact of DEB and other endovascular therapies for patients with femoral-popliteal disease. METHODS: A budget impact model was developed to compare the relative impact in Italy of four different index procedure treatments (PTA with regular balloons, DEB, bare metal stents (BMS) and drug eluting stents (DES)) based on the repeat procedure rates (TLR - target lesion revascularization) over 1 year. The model was developed from a Italian national healthcare system (NHS) perspective with a 5-year time horizon. A systematic literature review was carried out on TLR rates in patients with femoral-popliteal disease treated with one of the four treatment choices. Costs associated to each treatment are derived from the average DRG tariffs used for peripheral angioplasty procedures. A decision analytic model was developed to estimate total costs over 12 months of index procedures and possible revascularizations. RESULTS: Pooled 12-month TLR rates show clear patients benefit with DEB compared to PTA (8,6% vs 28,6%) and non-inferiority of DEB vs DES (9,4%) and BMS (11,5%). Total Italian DRG payments for index and repeat interventions (based on TLR rates estimation) across treatments showed that DEB was the least costly treatment strategy over 1 year, with saving of almost €1,000 per patient with DEB vs PTA. Based on these per-patient savings, the potential total savings amounted to approximately €2 million for an assumed annual increase of 5% in DEB adoption rate over 5 years. CONCLUSIONS: The analysis suggests clear patient benefit for DEB. Despite initial higher investments, DEB represents a cost-saving alternative to other technologies according to the NHS perspective.
Conference/Value in Health Info
2013-11, ISPOR Europe 2013, The Convention Centre Dublin
Value in Health, Vol. 16, No. 7 (November 2013)
Code
PCV40
Topic
Economic Evaluation
Topic Subcategory
Budget Impact Analysis
Disease
Cardiovascular Disorders